Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania. Show more

Location: 1717 Langhorne Newtown Road, Langhorne, PA, 19047, United States | Website: https://www.savarapharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

413.1M

52 Wk Range

$1.89 - $5.03

Previous Close

$2.30

Open

$2.28

Volume

1,084,244

Day Range

$2.24 - $2.42

Enterprise Value

336.8M

Cash

173.3M

Avg Qtr Burn

-23.91M

Insider Ownership

5.38%

Institutional Own.

98.53%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.